Herpes simplex virus type 2 (HSV2), a pathogen that causes genital herpes lesions, interferes with the host immune system via various known and unknown mechanisms. This virus has been used to study viral antigenic composition. Convalescent serum from HSV2-infected patients was used to identify viral antigens via 2-D protein electrophoresis and immunoblotting. The serum predominantly recognized several capsid scaffold proteins encoded by gene UL26.5, mainly ICP35. This protein has been primarily reported to function temporarily in viral assembly but is not expressed in mature virus particles. Further immunological studies suggested that this protein elicits specific antibody and cytotoxic T lymphocyte (CTL) responses in mice, but these responses do not result in a clinical protective effect in response to HSV2 challenge. The data suggested that immunodominance of ICP35 might be used to design an integrated antigen with other viral glycoproteins.

Keywords: herpes simplex virus type 2, ICP35, 2-D protein electrophoresis, immunization, viral replication

INTRODUCTION

Herpes simplex virus type 2 (HSV2), a human alpha-herpesviridae virus (Shukla and Spear, 2001), is known to spread in teenage and adult populations and to cause herpetic pathogenic lesions in the skin of the genitals (Looker et al., 2015), which can seriously impact quality of life (Castillo et al., 2020). Epidemic data have recently suggested that more than 400 million people are infected with HSV2 worldwide (James et al., 2020). Approximately 45 million infected patients have been identified in the United States, and this number increases by 1 million patients each year (Mathew and Sapra, 2020). Given this background and the lack of specific treatment methods (Sandgren et al., 2020), the development of HSV2 vaccines has become a major concern for the control of this disease (Spicknall et al., 2019); however, no applicable vaccine for HSV2 has been reported to date, although some clinical trials of a HSV2 vaccine have been initiated (Corey et al., 1999; Belshe et al., 2012). Based on the data from these trials, no protective effect has been observed in the individuals...
immunized with these experimental vaccines, although neutralizing antibodies were detected in serum samples (Corey et al., 1999; Belshe et al., 2012). These results suggest that our knowledge about how the HSV2 antigen trains the immune system to recognize and target the invading virus is lacking. Studies of HSV2 pathogenesis have indicated that various proteins expressed during viral infection are capable of interacting with the host immune system and interfering with antiviral immunity (Suazo et al., 2015), although these viral proteins should be recognized by the immune system and elicit specific responses, such as specific antibody responses against each viral protein (Tognarelli et al., 2019). Thus, understanding the mechanism of host immunity against this virus depends upon integrated analyses of the immune recognition of the majority of its proteins and the roles played by these proteins during infection. Based on this hypothesis, antibodies were used in neutralizing assays and enzyme-linked immunosorbent assays (ELISAs) to evaluate the immunological antibody responses against each viral protein (Tognarelli et al., 2015), although these viral proteins should be recognized by the immune system and elicit specific responses, such as specific antibody responses against each viral protein (Tognarelli et al., 2019). Thus, understanding the mechanism of host immunity against this virus depends upon integrated analyses of the immune recognition of the majority of its proteins and the roles played by these proteins during infection. Based on this hypothesis, antibodies were used in neutralizing assays and enzyme-linked immunosorbent assays (ELISAs) to evaluate the immunological reactions that occur during HSV2 infection; however, these methods were insufficient to show the relationships of various viral proteins and immune serum. Here, we used protein 2-D electrophoresis and immunoblotting associated with immunofluorescent assay to investigate the recognition of viral proteins by convalescent serum collected from HSV2-infected patients. Interestingly, we found that several viral capsid scaffold proteins encoded by genes UL26.5 and UL26, especially ICP35, were predominantly recognized by the convalescent serum compared with other viral structural proteins that elicit neutralizing antibodies (Cairns et al., 2015). Moreover, further immunological characterization of ICP35 suggested the possibility that immunodominance might be used to design an integrated antigen with other viral glycoproteins.

MATERIALS AND METHODS

Virus and Cells

The HSV2 HG52 strain was purchased and preserved by the Virus Immunization Room of the Institute of Medical Biology, Chinese Academy of Medical Sciences. The virus was grown in Vero cells (ATCC, Manassas, USA), which were cultured in an incubator at a constant temperature of 37°C using Dulbecco’s modified Eagle medium (DMEM; Corning, NY, USA) supplemented with 5% fetal bovine serum (FCS; HyClone, Logan, USA), 100 U/ml penicillin, and 100 µg/ml streptomycin.

Viral Titration

All experimental procedures were performed under BSL-2 laboratory conditions. Virus samples were serially diluted 10-fold with serum-free DMEM. Different viral dilutions were added to a 96-well plate. Each dilution (100 µl per well) was added to 8 parallel wells. Then, 100 µl of Vero cell suspension was added to each well at a concentration of 2.5 × 10⁵ cells/ml. After the plate was incubated at 37°C in 5% CO₂ for 7 days, the cytopathic effect (CPE) was observed and assessed with an inverted microscope (Nikon, Tokyo, Japan).

Neutralizing Antibody Test

Heat-inactivated serum was diluted and coincubated with live virus (100 lgCCID₅₀/well) for 2 h at 37°C, and then, 100 µl Vero cells (10⁷/mL) were added. Then, the plates were incubated at 37°C in 5% CO₂ for 7 days. The CPEs were observed and assessed with an inverted microscope (Nikon) to determine the neutralizing antibody titer of the serum. The geometric mean titers (GMTs) of the neutralizing antibodies were measured.

Plaque Assay

HSV2 virus (MOI=1) and serum samples were added to a 6-well plate with a confluent monolayer of cells and coincubated for 2 h. Then, the plate was incubated at 37°C in 5% CO₂ for 2-3 days after a mixture of 2× DMED and 2% methylcellulose was added. Plaques could be observed after staining with crystal violet dye.

Viral Purification

Monolayers of Vero cells were infected with HSV2 at a MOI of 1, and at 48 h postinfection, the virus liquid was harvested. The virus liquid was concentrated by Millipore Centricron Plus-70. The concentrated virus liquid was layered on a 15 to 55% iodixanol gradient and centrifuged at 30,000 rpm in an SW41 rotor for 2.5h. The purified virus samples were observed via electron microscopy and were harvested at -80°C.

Immunofluorescence

When the 293 cells were 70%-90% confluent, they were transfected with the eukaryotic vectors of intact ICP35, VP22a and VP24 according to the Lipofectamine™ 3000 Reagent Protocol in glass bottom cell culture dishes, and the samples were harvested at 18h. In addition, Vero cells were infected with the HSV2 virus at an MOI of 0.2, and the samples were harvested at 4h, 12h, 24h postinfection. These dishes were fixed in 4% paraformaldehyde for 30 min and then blocked using 4% bovine serum albumin (BSA). For detection of the HSV-2 ICP35, VP22a, VP24 antigen and trace ICP35 protein during viral infection, the dishes were sequentially incubated with primary antibody convalescent serum, immune serum of ICP35 and secondary antibody Alexa Fluor® 647 Goat pAb to Rb IgG (Lot: GR33281 42-4, Abcam), Alexa Fluor® 488 Goat anti-human IgG (H +L) (Lot: 2196582, Invitrogen). All cell nuclei were detected with DAPI. Fluorescence was visualized and analyzed using a confocal microscope (TCS SP2, Leica).

Co-Immunoprecipitation

Vero cells were infected with the HSV2 virus at an MOI of 1. At the indicated time points (8, 14 and 20 h p.i.), the cells were washed with PBS and lysed in 1 ml RIPA lysis buffer for 10 min. The lysates were centrifuged (12,000 rpm, 4°C for 10 min) and pre cleared with 50 µl of control agarose beads. After centrifugation, the cell lysate supernatants were incubated overnight with the anti-ICP35 antibody or negative control at 4°C with rotation. Pretreated protein A+G beads (50 µl) were added, and the samples were incubated at 4°C for an additional 2 h and then washed five times and eluted with 500 µl of Tris-EDTA buffer containing 1% SDS. The DNA was then extracted and analyzed using real-time PCR. The specific primer sets used are listed in Table 1.
**2D Protein Electrophoresis and Western Blot Analysis**

Purified HSV2 virus samples were lysed with 2D protein lysis buffer (8 M urea, 4% CHAPS, 100 mM DTT, and 2% IPG buffer). The total protein concentration was determined using a bicinchoninic acid (BCA) protein concentration determination kit (Beyotime Biotechnology, Shanghai, China). The sample was separated by the IPGphor 2D protein gel system (GeHealthcare, Chicago, USA) according to the manufacturer’s instructions. Approximately 80 µg of protein in 170 µL of hydration solution was separated with the IPGphor kit (Immobiline DryStrip, GE Healthcare, USA) covering the pH range 4-7. Then, the protein was separated by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred to polyvinylidene fluoride (PVDF) membranes, blocked with 5% skim milk (prepared in TBST), incubated with convalescent serum from clinically diagnosed HSV2 patients, and incubated with peroxidase-conjugated AffiniPure rabbit anti-human IgA + IgG + IgM (H+L) (Jackson, USA). The PVDF membranes were incubated with an ECL ultrasensitive chemiluminescence reagent and placed in a Bio-Rad gel imager for exposure and color development.

**Silver Stain**

The reaction system of each glue in the silver dyeing process is 250ml. The dyeing procedure and the preparation of the solution required for each step are as follows: fix (25ml acetic acid, 100ml methanol, 125ml milli-Q water) twice, 15 minutes each time; sensitize (75ml methanol, 0.5g Na2S2O3, 17g NaAc, milli-Q water to 250ml) for 30 minutes; rinse (250ml milli-Q water) 3 times, 5 minutes each time; silver dyeing (0.625g AgNO3, milli-Q water to 250ml) 30 minutes; rinse (250ml milli-Q water) 2 times, 1 minute each time; color development (6.25g Na2CO3, 100ml formaldehyde, milli-Q water to 250ml) 4 minutes; stop solution (3.65g EDTA, milli-Q water to 250ml) for 10 minutes; after rinsing (250ml milli-Q water) for 1 minute, use Image Scanner III to scan and save the pictures, and use ImageMaster 2D platinum 7.0 software to analyze and screen out the required protein gel spots.

**ICP35 Recombinant Protein**

The ICP35 recombinant protein was constructed with the prokaryotic expression vector pET-32a (+) (Solarbio, Beijing, China), which was purified with the Beyotime His Tag Protein Product Purification Kit (Beyotime Biotechnology, China). The sequences of the primers used are listed in Table 1.

**Animals**

Mice: Four-week-old female BALB/c mice (Beijing Vital River Laboratory Animal Technologies Co. Ltd., Beijing, China) were used in this study. The mice were anesthetized by inhalation of 2% isoflurane for all the procedures, and every effort was made to minimize suffering. The mice were bred in strict accordance with the standard procedures for breeding laboratory animals.

**Ethics**

Human experiments: Convalescent serum samples were collected from patients diagnosed with HSV2 infection at the First Affiliated Hospital of Kunming Medical University, and the patients provided informed consent. The protocols were reviewed and approved by the Experimental Management Association of the IMB, CAMS (approval number: DWSP 201803018-1).

Animal experiments: The animal experiments were designed and performed according to the principles in the “Guide for the Care and Use of Laboratory Animals” and in the “Guidance for Experimental Animal Welfare and Ethical Treatment”. The protocols were reviewed and approved by the Experimental Animal Management Association of the IMB, CAMS (approval number: DWSP 201902030-1). All the animals were completely under the care of veterinarians at the IMB, CAMS. The study was adhered to standard biosecurity and institutional safety procedures and has appropriated equipment and facilities.

**Immunization and Viral Challenge**

Mice were randomly divided into three groups and intramuscularly immunized with 20 µg of purified ICP35 (the purified ICP35 protein concentration was determined by BCA) (n=30) or with Al(OH)3 adjuvant alone (n=30) used as a control, and PBS negative control (n=10), on days 0, 28 and 42. The serum samples were obtained at 7 and 28 days after immunization. The mice were infected with HSV2 virus on day 7 after the booster injection except negative control. HSV2 infection (2x10^7 CCID50/mouse) via the vaginal route was performed on the mice immunized with the ICP35 protein or with the adjuvant control. All the animals were monitored daily to observe their clinical symptoms. For weight observation group (n=10 per group), the mice were monitored daily after challenge to observe body weight and survival rate. For experimental sampling group (n=20 per group), the routine vaginal secretion, tissue and blood samples were collected 1 day, 3 days, 5 days, 7 days and 15 days after infection for subsequent testing and neutralization assays. Three mice were euthanized in each group at one time point. All remaining mice were euthanized at the end of the experiment.

**ELISPOT**

An ELISPOT assay was performed with the Mouse IFN-γ/IL-4 ELISPOT Kit (Mabtech, Cincinnati, USA) according to the manufacturer’s protocol. Briefly, peripheral blood mononuclear cells (PBMCs) were isolated from mouse spleens by lymphocyte isolation (Dakewe, China) and plated in duplicate wells. Purified HSV2 ICP35 recombinant protein and the positive stimulus phytohemagglutinin (PHA) were added at a concentration of 5 µg/well to 96-well plates precoated with IFN-γ and IL-4. The plates were incubated at 37°C for 24 h in a carbon dioxide incubator. Then, the cells were removed, and the spots were developed. The colored spots were counted with an ELISPOT reader (CTL, Shaker Heights, OH, USA).

---

**Table 1** | The qRT-PCR primers and ICP35 plasmid construction.

| Name        | Sequence (5’ - 3’)               |
|-------------|----------------------------------|
| HSV2-Gg-F   | CGCCTCCGTAATGCGCTTCCCT           |
| HSV2-Gg-R   | TCTACCCACAACAGACACCAAGG          |
| HSV2-Gg-Probe | FAM-CCCGAGAATCGAGCTGACCGAGATCG-BHQ1 |
| HSV-2-UL26.5-F | ATAGAATTCATGAACCCGTTTCGGCATC   |
| HSV-2-UL26.5-R | GGAAAGCTTTTTATTTATGAAAACACACA |

F, Forward primer; R, Reverse primer.
Quantification of the Viral Load by q-RT-PCR

Total DNA was extracted from blood and tissue samples from the experimental mice with an Axygen® AxyPrep Body Fluid Viral DNA/RNA Miniprep Kit (Axygen®, USA). According to the protocol, the primers used for q-RT-PCR were designed to be specific for the gG sequences in the HSV2 genome (Table 1). q-RT-PCR was performed using the Takara Premix Ex Taq™ (Probe qPCR) Kit (TaKaRa, China).

Electron Microscopy

HSV2 virus was purified by iodixanol density gradient centrifugation. Postfixation, en bloc contrasting, dehydration and embedding in epoxy resin were done following a standard protocol (Laue, 2010). Samples were stained with 1% phosphotungstic acid and observed by transmission electron microscopy (Hitachi, Kyoto, Japan).

Statistical Analysis

The data are shown as the mean and standard deviation. GraphPad Prism software (San Diego, CA, USA) and the t test were used for the statistical analyses.

RESULTS

Recognition of Viral-Encoded Proteins by Convalescent Serum From HSV2-Infected Patients

Specific neutralizing antibodies, as certain indicators of antiviral immunity, reflect the recognition of key viral antigens, the main structural proteins that enable a virus to bind to receptors in the cell membrane, by the host immune system (Klasse, 2014). We performed protein 2-D electrophoresis and immunoblotting experiments with convalescent serum that was prepared by mixing 5 sera samples and showed a neutralizing antibody titer of 1:32 (Supplemental Table 1). Purified HSV2 was produced and harvested from infected Vero cells at different time points and was shown to contain various particles including those from different infectious stages (Figure 1A). This viral infectious sample was recognized by the convalescent serum, as indicated by the complicated antigenic map with multiple spots (Figures 1B, C). These spots were further identified using mass spectrometry, and various molecules of different sizes encoded by genes UL26.5 and UL26, including ICP35, VP22a and VP24, were recognized in the immunoblots (Table 2). In addition, other viral proteins, including some viral molecules that function during infection, such as TK, and structural components of the capsid, were recognized; however, only weak signals of glycoproteins that elicit neutralizing antibodies were observed in the blots (Table 2). Because ICP35 was thought to exist in immatted virus particles (Thomsen et al., 1995), we further purified the virus harvest using isodensity centrifugation to separate two different particles and performed immune-blotting with convalescent serum. The results showed that only trace levels of ICP35 were detected in matured particles compared to the other particles (Figures 1D–F), while the prokaryotic expressed ICP35 was recognized by convalescent serum in immune-blotting, either by immune serum of ICP35 (Figure 1G). To identify these data, we using convalescent serum and immune serum of expressed ICP35 traced the proteins encoded by UL26 gene during viral infection, the result of immune-fluorescent observation suggested that both sera were capable of recognizing the proteins encoded by UL26 gene including ICP35 during viral infection (Figure 1H). While the intact ICP35, VP22a and VP24 expressed in 293 cells were recognized by both sera (Figure 1I). These data comprehensively suggested that the viral proteins including ICP35 encoded by UL26 gene showed distinct immunogenicity during infection.

Study of the Immune Response Elicited by ICP35

To further immunologically characterize ICP35, we used BALB/c mice immunized with the prokaryotically expressed ICP35. The mice were administered three inoculations of 20 µg/dose into muscular tissue at intervals of 4 and 2-weeks (Figure 3A). The neutralizing antibodies were detected using a plaque assay at days 7 and 28 after the last immunization, and no positive results were observed at these two time points; however, the addition of serum to the assay restricted the sizes of the plaques, even if it did not decrease the virus titers (Figure 3B). ELISPOT was used to detect IFN-γ and IL-4 production at day 28 post immunization, and the results suggested a positive T cell response against this protein and against the purified virus harvested from infected Vero cells (Figures 3C, D). In a further study of the interaction between the serum and the viral antigen, viral particles harvested from infected Vero cells were incubated with the serum and were shown to contain viral genome but were noninfectious (Figures 3E, F). These results suggested that ICP35 is an effective viral antigenic protein but is not a neutralizing antigen.
Immunization With ICP35 Attenuates the Clinical Symptoms in Mice Challenged With HSV2

To immunologically characterize HSV2, we infected BALB/c mice immunized with the expressed ICP35 protein with HSV2. The HSV2 HG52 strain was used to infect two groups of immunized mice via the vaginal route. The low-dose group received $1 \times 10^4$ CCID$_{50}$/mouse while the high-dose group, which was used to assess the survival rate, received $2 \times 10^4$ CCID$_{50}$/mouse, and similar groups were established as positive controls (Figure 3A). After infection, the mice were monitored daily to observe their symptoms. The mice in the immunized and control groups presented decreasing body weights. Beginning on day 7, this trend differed between the experimental and control groups (Figure 4A). By day 15, the experimental and control groups showed similar survival rates (Figure 4B). Interestingly, a difference was observed in the local tissues of the infected vaginas. In the immunized mice, these tissues presented weaker inflammatory reactions without exudation, but in the control mice, these tissues presented obvious inflammation with exudation (Figure 4C). The detection of viral load via vaginal swabs also supported the clinical features described above (Figure 4D). These results suggested that the immune response elicited by ICP35 contributed, to some extent, to antiviral immunity.
Viral Proliferation and the Resulting Pathological Damage in Various Tissues of ICP35 Protein-Immunized Mice
We sacrificed the immunized and control mice at 1, 3, 5, 7 and 15 days after low-dose viral challenge and detected the viral loads of various tissues. The results suggested that the viral loads in various tissues of the immunized mice, especially that in the vaginal tissue, were lower than those in the positive control mice, although these particles showed similar dynamic proliferative processes (Figures 5A–J). Histopathological observation suggested that viral challenge led to varying degrees of pathological inflammatory reactions in various tissues in the immunized and control mice (Table 3). Observation of the local vaginal tissue did not reveal invasive pathological lesions in the epithelial structure of the immunized mice, although there was infiltration of inflammatory cells; however, invasive tissue lesions associated with inflammatory reactions were found in the vaginal epithelial tissues of the control mice (Figure 6). These results suggested that the immunity induced by ICP35 did restrict viral pathogenesis to some extent.

DISCUSSION
HSV2, a pathogen that spreads in populations via sexual contact and causes herpes progenitalis (Ahmed et al., 1982), has been studied due to its various strategies for interfering with the host immune system (Peng et al., 2009; Stefanidou et al., 2013; Stempel et al., 2019). Although our accumulated knowledge about these strategies allows us to understand some mechanisms by which the virus evades immune recognition and avoids immune attack, there are some unknown mechanisms that hinder the strategic study of HSV2 vaccines (Johnston et al., 2016). For instance, although specific neutralizing antibodies are elicited and are an important immunological indicator for the evaluation of individuals infected or immunized with HSV2 or vaccine antigens, these antibodies do not provide clinical protective effects during virus infection (Diebolder et al., 2014), suggesting a more complicated mechanism by which the virus interferes with the immune system. Based on this background, our work first investigated the recognition of virus-encoded protein antigens in infected cells by antibodies in the convalescent

---

**TABLE 2 | Mass spectrometric identification of 2-D protein gel electrophoresis spots.**

| Spot number | Gene | Uniprot ID | Description |
|-------------|------|------------|-------------|
| N1          | MCP  | P89442     | Major capsid protein |
| N2          | MCP  | P89442     | Major capsid protein |
| N3          | UL26.5 | G91248     | Capsid scaffolding protein |
| N4          | UL42  | P89463     | DNA polymerase processivity factor |
| N5          | UL26.5 | G91248     | Capsid scaffolding protein |
| N6          | TK    | P89446     | Thymidine kinase |
| N7          | TK    | P89446     | Thymidine kinase |
| N8          | TK    | P89446     | Thymidine kinase |
| N9          | DBP   | P89452     | Major DNA-binding protein |
| N10         | UL26.5 | G91248     | Capsid scaffolding protein |
| N11         | UL26.5 | G91248     | Capsid scaffolding protein |
| N12         | UL26.5 | G91248     | Capsid scaffolding protein |
| N13         | UL26.5 | G91248     | Capsid scaffolding protein |
| N14         | UL26.5 | G91248     | Capsid scaffolding protein |
| N15         | UL26.5 | G91248     | Capsid scaffolding protein |
| N16         | UL26.5 | G91248     | Capsid scaffolding protein |
| N17         | UL26.5 | G91248     | Capsid scaffolding protein |
| N18         | UL26.5 | G91248     | Capsid scaffolding protein |
| N19         | UL26.5 | G91248     | Capsid scaffolding protein |
| N20         | DBP   | P89452     | Major DNA-binding protein |
| N21         | DBP   | P89452     | Major DNA-binding protein |
| N22         | DBP   | P89452     | Major DNA-binding protein |
| N23         | DBP   | P89452     | Major DNA-binding protein |
| N24         | UL26.5 | G91248     | Capsid scaffolding protein |
| N25         | DBP   | P89452     | Major DNA-binding protein |
| N26         | DBP   | P89452     | Major DNA-binding protein |
| N27         | DBP   | P89452     | Major DNA-binding protein |
| N28         | DBP   | P89452     | Major DNA-binding protein |
| N29         | UL26.5 | G91248     | Capsid scaffolding protein |
| N30         | DBP   | P89452     | Major DNA-binding protein |
| N31         | DBP   | P89452     | Major DNA-binding protein |
| N32         | UL42  | P89463     | DNA polymerase processivity factor |
| N33         | UL42  | P89463     | DNA polymerase processivity factor |
| N34         | UL42  | P89463     | DNA polymerase processivity factor |
| N35         | DBP   | P89452     | Major DNA-binding protein |
| N36         | DBP   | P89452     | Major DNA-binding protein |
| N37         | DBP   | P89452     | Major DNA-binding protein |
| N38         | gD    | O694467    | Envelope glycoprotein D |
serum from HSV2-infected patients via 2-D electrophoresis and immunoblotting. We expected to primarily identify the remnant viral structural proteins with significant immunogenicity. Interestingly, we observed a clear trend that the antibodies in the convalescent serum recognized the viral capsid scaffold protein ICP35 and other similar proteins encoded by genes UL26.5 and UL26. ICP35 is thought to be a capsid structural protein that temporarily functions in capsid during viral assembly (Thomsen et al., 1995). Importantly, ICP35 actually is not expressed in mature virion (Thomsen et al., 1995), which means that it does not contribute to the antigenicity or immunogenicity of mature HSV2 virion. Our further work using the prokaryotic expression method and immunological studies characterized the antigenicity of this protein and showed that the elicited immunity was unable to control viral proliferation in mouse tissues via antibody and specific cytotoxic T lymphocyte (CTL) responses, although it did attenuate the clinical symptoms of local tissues to some

![Image](https://www.frontiersin.org)
FIGURE 3 | The integrated immune responses elicited by ICP35. (A) Schematic of ICP35 immunization and viral challenge protocols in the mice. (B) The addition of anti-ICP35 antibody restricted the sizes of the plaques. The positive control refers to HSV2 and normal serum samples; ICP35 antibody+HSV-2 refers to HSV2 and anti-ICP35 serum samples. (C) The ELISPOT analysis of ICP35 elicited IFN-γ-secreting T cell responses in ICP35 protein-immunized mice at day 28 after the last immunization (n=3). The spot diagram (left) and result (right) of IFN-γ were shown. Samples from the ICP35-immunized animals were stimulated with the ICP35 recombinant protein and purified HSV-2 protein. Samples were run in duplicate. (D) The ELISPOT analysis of ICP35 elicited IL-4-secreting T cell responses in ICP35 protein-immunized mice at day 28 after the last immunization (n=3). The spot diagram (left) and result (right) of IL-4 were shown. Samples from the ICP35-immunized animals were stimulated with the ICP35 recombinant protein and purified HSV-2 protein. Samples were run in duplicate. (E) Fluorescence quantitative PCR of protein A agarose gel particle sediment. -ICP35 antibody + protein A: the cell lysate supernatants infected HSV2 were incubated overnight without the anti-ICP35 antibody at 4°C. +ICP35 antibody + protein A: the cell lysate supernatants infected HSV2 were incubated overnight with the anti-ICP35 antibody at 4°C. (F) Plaque assay of protein A agarose gel particle sediment. The positive control refers to infection with HSV2 virus. The negative control refers to cells. -ICP35 antibody + Protein A: the cell lysate supernatants infected HSV2 were incubated overnight without the anti-ICP35 antibody at 4°C. +ICP35 antibody + protein A: the cell lysate supernatants infected HSV2 were incubated overnight with the anti-ICP35 antibody at 4°C. **P<0.01, ***P<0.001.
FIGURE 4 | Immunization with ICP35 attenuated the clinical symptoms in mice challenged with HSV2. (A) The mice were monitored daily after challenge to observe their symptoms (n=10/group). Decreased body weight was observed in the immunized with ICP35 (ICP35+HSV-2), with Al(OH)3 adjuvant groups (HSV-2) and PBS negative control groups (PBS), but beginning on day 7, this trend differed between the experimental and control groups. The data are the mean of ten independent animals. *P<0.05, **P<0.01, ***P<0.001 vs. PBS. (B) The survival rate of mice challenged with HSV2 was monitored daily (n=10/group). Death occurred in the Al(OH)3 adjuvant groups (HSV-2) beginning on day 9, and death occurred in the ICP35 immunized group (ICP35+HSV-2) beginning on day 11. ***P<0.001. (C) The clinical symptoms of the mice challenged with HSV2 in the immunized with ICP35 (ICP35+HSV-2) and with Al(OH)3 adjuvant groups (HSV-2), PBS group without challenge as negative control. (D) The detection of the viral load by vaginal swab in the immunized with ICP35 (ICP35+HSV-2) and with Al(OH)3 adjuvant groups (HSV-2) after viral challenge. The data are the mean ± SD of three independent animals.

FIGURE 5 | Viral proliferation in various tissues of the ICP35 protein-immunized or control mice. (A–J) The viral loads in various tissues of the immunized mice with ICP35 (ICP35+HSV-2), especially those in the vaginal tissues, were lower than those in various tissues of the mice with Al(OH)3 adjuvant (HSV-2). (A) Brain, (B) TG, (C) Spinal cord, (D) Dorsal root ganglion, (E) Vagina, (F) Lymphaden, (G) Heart, (H) Liver, (I) Lung, (J) Kidney. The data shown in (A–J) are the mean ± SD of three independent animals. *P<0.05, **P<0.01, ***P<0.001.
extent. These data provided us with the technical possibility that the immunodominance of ICP35 might be used to design an integrated antigen with other viral glycoproteins, but further studies are needed to clarify the function of this protein in viral interference with host immunity.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Experimental Management Association of the IMB, CAMS. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Experimental Animal Management Association of the IMB, CAMS.

AUTHOR CONTRIBUTIONS

QL, YZ, and WD conceived and designed the study. XL and JW performed the experiments and analyzed the data. TM, YG, YZ, LW, SF, XLX, GJ, PC, XXX, SD, JZ, DL, YL, LY, HZ, ML, HLZ, RG contributed reagents, materials and analysis tools. QL wrote and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China (No. 31670173 and No.81802868) and grant from the Major Science and Technology Special Projects of Yunnan Province (No.202002AA100009).

ACKNOWLEDGMENTS

We would like to thank Yunguang Hu and Xi Wang for technical help.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2021.649722/full#supplementary-material
REFERENCES

Ahmed, A. R., Strom, H., Bierman, S., Myers-Elliot, R., Tiwari, P., and Terasaki, P. I. (1982). A Study of HLA and DRw Antigens in Severe Recurrent Herpes Genitalis (HSV-2) Infection. J. Am. Acad. Dermatol. 6 (5), 898–901. doi: 10.1016/0190-9622(82)70079-9

Belshe, R. B., Leone, P. A., Bernstein, D. I., Wald, A., Levin, M. J., Stapleton, J. T., et al. (2012). Efficacy Results of a Trial of a Herpes Simplex Vaccine. N Engl. J. Med. 366 (1), 34–43. doi: 10.1056/NEJMoa1103151

Cairns, T. M., Huang, Z. Y., Gallagher, J. R., Lou, H., Whitbeck, J. C., et al. (2015). Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific. J. Virol. 89 (18), 9213–9231. doi: 10.1128/jvi.01213-15

Castillo, E., Duarte, L. F., Corrales, N., Alvarez, D. M., Farias, M. A., Henriquez, A., et al. (2020). Anti-Herptic Activity of Macrocytis Pyrifera and Durvillaea Antarctica Algae Extracts Against HSV-1 and HSV-2. Front. Microbiol. 11:2006. doi: 10.3389/fmicb.2020.02006

Corey, L., Langenberg, A. G., Ashley, R., Sekulovich, R. E., Izu, A. E., Douglas, J. M.J., et al. (1999). Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection: Two Randomized Controlled Trials. Chiron Hsv Vaccine Study Group. JAMA 282 (4), 331–340. doi: 10.1001/jama.282.4.331

Diebold, P., Keller, A., Haase, S., Schlegelmilch, A., Kiefer, J. D., Karimi, T., et al. (2014). Generation of “Lymph Node Derived Antibody Libraries” (LYNDAL) for Selecting Fully Human Antibody Fragments With Therapeutic Potential. MAbs 6 (1), 130–142. doi: 10.4161/mabs.27236

James, C., Harfouche, M., Welton, N. J., Turner, K. M., Abu-Raddad, L. J., Gottlieb, S. L., et al. (2020). Herpes Simplex Virus: Global Infection Prevalence and Incidence Estimate. Bull. World Health Organ 98 (5), 315–329. doi: 10.2471/blt.19.237149

Johnston, C., Gottlieb, S. L., and Wald, A. (2016). Status of Vaccine Research and Development of Vaccines for Herpes Simplex Virus. Vaccine 34 (26), 2948–2952. doi: 10.1016/j.vaccine.2015.12.076

Klasse, P. J. (2014). Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Adv. Biol. 2014:157895. doi: 10.1155/2014/157895

Laue, M. (2010). Electron Microscopy of Viruses. Methods Cell Biol. 96, 1–20. doi: 10.1016/S0091-679X(10)60001-9

Looker, K. I., Magaret, A. S., Turner, K. M., Vickerman, P., Gottlieb, S. L., and Newman, L. M. (2015). Global Estimates of Prevalent and Incident Herpes Simplex Virus Type 2 Infections in 2012. PLoS One 10 (1), e114989. doi: 10.1371/journal.pone.0114989

Mathew, J.F, and Sapra, A. (2020). “Herpes Simplex Type 2,” in StatPearls (Treasure Island (FL: StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC).

Peng, T., Zhu, J., Klock, A., Phasouk, K., Huang, M. L., Koelle, D. M., et al. (2009). Evasion of the Mucosal Innate Immune System by Herpes Simplex Virus Type 2. JVI.69.6.3690-3703.1995

Sandgren, K. J., Truong, N. R., Smith, J. B., Bertram, K., and Cunningham, A. L. (2020). Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology. Methods Mol. Biol. 2060, 31–56. doi: 10.1007/978-1-4939-9814-2_2

Shukla, D., and Spear, P. G. (2011). Herpesviruses and Heparan Sulfate: An Intimate Relationship in Aid of Viral Entry. J. Clin. Invest. 108 (4), 503–510. doi: 10.1172/jci13799

Spicknall, I. H., Looker, K. J., Gottlieb, S. L., Chesson, H. W., Schiffer, J. T., Elmes, J., et al. (2019). Review of Mathematical Models of HSV-2 Vaccination: Implications for Vaccine Development. Vaccine 37 (50), 7396–7407. doi: 10.1016/j.vaccine.2018.02.067

Stefanidou, M., Ramos, L., Mas Casullo, V., Trépanier, J. B., Rosenbaum, S., Fernandez-Sesma, A., et al. (2013). Herpes Simplex Virus 2 (HSV-2) Prevents Dendritic Cell Maturation, Induces Apoptosis, and Triggers Release of Proinflammatory Cytokines: Potential Links to HSV-HIV Synergy. J. Virol. 87 (3), 1443–1453. doi: 10.1128/jvi.01302-12

Stempel, M., Chan, B., and Brinkmann, M. M. (2019). Coevolution Pays Off: Herpesviruses Have the License to Escape the DNA Sensing Pathway. Med. Microbiol. Immunol. 208 (3-4), 495–512. doi: 10.1007/s00430-019-00582-0

Suazo, P. A., Ibañez, F. J., Retamal-Diaz, A. R., Paz-Fiblas, M. V., Bueno, S. M., K.Vergis, A. M., et al. (2015). Evasion of Early Antiviral Responses by Herpes Simplex Viruses. Mediators Inflamm. 2015:593757. doi:10.1155/2015/593757

Thomsen, D. R., Newcomb, W. W., Brown, J. C., and Homa, F. L. (1995). Assembly of the Herpes Simplex Virus Capsid: Requirement for the Carboxyl-Terminal Twenty-Five Amino Acids of the Proteins Encoded by the UL26 and UL26.5 Genes. J. Virol. 69(6):3690–3703. doi: 10.1128/ JVI.69.6.3690-3703.1995

Tognarelli, E. I., Palomino, T. F., Corrales, N., Bueno, S. M., Kalergis, A. M., and González, P. A. (2019). Herpes Simplex Virus Evasion of Early Host Antiviral Responses. Front. Cell Infect. Microbiol. 9:127. doi: 10.3389/fcimb.2019.00127

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.